Altre lingue Poseida Therapeutics, Inc.

Azioni

PSTX

US73730P1084

Mercato chiuso - Nasdaq Altri mercati azionari 22:00:00 25/04/2024			Variaz. 5gg	Var. 1 gen.
2,05 ^USD	-0,97%		+2,50%	-38,99%

08/04	Poseida Therapeutics, Inc. Presenta nuovi dati di Fase 1 all'AACR 2024, a sostegno del potenziale della terapia CAR-T allogenica P-BCMA-Allo1 per un'ampia gamma di pazienti con mieloma multiplo.	CI
25/03	Poseida Therapeutics, Inc nomina Syed Rizvi come Chief Medical Officer con effetto dal 1° aprile 2024	CI

Altre lingue

Sblocca tutte le notizie su tutte le aziende: non perdere mai più un'opportunità di investimento redditizia!

Registrazione 100% gratuita

Poseida Therapeutics Announces Strong Lineup of Presentations at the American Society of Gene and Cell Therapy 27th Annual Meeting	19/04
Poseida Therapeutics Hosts Gene Therapy R&D Day Highlighting New Scientific Advancements and Pipeline Focus	17/04
Poseida Therapeutics, Inc. Presents New Phase 1 Data at AACR 2024 Supporting Potential of P-BCMA-Allo1 Allogeneic CAR-T Therapy to Benefit Broad Range of Patients with Multiple Myeloma	08/04
Poseida Therapeutics Announces Inducement Grant Under Nasdaq Listing Rule 5635(c)(4)	01/04
Poseida Therapeutics Appoints Syed Rizvi as Chief Medical Officer	25/03
Poseida Therapeutics, Inc Appoints Syed Rizvi as Chief Medical Officer Effective April 1, 2024	25/03
Poseida Therapeutics to Present at H.C. Wainwright 2nd Annual Cell Therapy Virtual Conference	19/03
Poseida Therapeutics, Inc. Reports Earnings Results for the Full Year Ended December 31, 2023	07/03
Earnings Flash (PSTX) POSEIDA THERAPEUTICS Reports Q4 Revenue $25M	07/03
Poseida Therapeutics : Provides Updates and Financial Results for the Fourth Quarter and Full Year 2023 - Form 8-K	07/03
Poseida Therapeutics, Inc. Announces Executive Changes	07/03
Poseida Therapeutics, Inc. Reports Earnings Results for the Fourth Quarter Ended December 31, 2023	07/03
Poseida Therapeutics Announces Inducement Grant Under Nasdaq Listing Rule 5635(c)(4)	04/03
Poseida Therapeutics, Inc.(NasdaqGS:PSTX) dropped from NASDAQ Biotechnology Index	15/12
Poseida Therapeutics Reports Positive Results of Phase 1 Blood Cancer Treatment Trial	11/12
Poseida Therapeutics Shares Climb on Positive Data for Blood Cancer Treatment	11/12
Poseida Therapeutics, Inc. Presents Positive Early Results from its Phase 1 Trial of Allogeneic CAR-T P-BCMA-ALLO1 in Relapsed-Refractory Multiple Myeloma at the 65th American Society of Hematology Annual Meeting	10/12
Earnings Flash (PSTX) POSEIDA THERAPEUTICS Posts Q3 Revenue $9.4M	09/11
Poseida Therapeutics, Inc. Reports Earnings Results for the Third Quarter and Nine Months Ended September 30, 2023	09/11
Poseida Therapeutics to Present at Two Upcoming Investor Conferences	07/11

Non ci sono risultati per questa ricerca

Tutte le notizie Raccomandazione analisti Eventi più importanti Insiders Resoconti Comunicati stampa Pubblicazioni ufficiali Altre lingue Idee di trading Articoli MarketScreener Analisi MarketScreener

Altre lingue Poseida Therapeutics, Inc.

Azioni

PSTX

US73730P1084

Altre lingue

Filtri